adMare
News

adMare BioInnovations Welcomes 22 Influential Life Sciences Leaders to Cohort VI of the adMare Academy Executive Institute 

CASTL Opens Biomanufacturing Training Facility in Quebec

The adMare Institute Examines the Critical Role of Anchor Companies in Building Globally Competitive Life Sciences Innovation Ecosystems 

Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions

adMare BioInnovations Launches the Refreshed Version of the adMare Community with New Engaging Features

adMare BioInnovations and MaRS Discovery District Welcome Inaugural Ontario Start-Ups to Therapeutics Accelerator Program

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

adMare BioInnovations Appoints John DeLucchi, Martin LeBlanc, and Tim van Biesen to the Board of Directors

Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial

– ZONE study to evaluate the effect of ZT-01 on preventing nighttime hypoglycemia in people with Type 1 diabetes –

– ZT-01 has the potential to become the first therapeutic to prevent nocturnal hypoglycemia, a condition for which there are currently no available therapies –

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study.

adMare BioInnovations invites early-career science professionals to apply to the BioInnovation Scientist (BIS) Program: Foundations Cohort II

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.